Open AccessP1161: ASPEN: LONG‐TERM FOLLOW‐UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
Author(s) -
Dimopoulos M.,
Opat S.,
D'Sa S.,
Jurczak W.,
Lee H.P.,
Cull G.,
Owen R. G.,
Marlton P.,
Wahlin B. E.,
GarciaSanz R.,
McCarthy H.,
Mulligan S.,
Tedeschi A.,
Castillo J. J.,
Czyz J.,
Fernandez De Larrea Rodriguez C.,
Belada D.,
Libby E.,
Matous J.,
Motta M.,
Siddiqi T.,
Tani M.,
Trneny M.,
Minnema M.,
Buske C.,
Leblond V.,
Treon S. P.,
Trotman J.,
Chan W. Y.,
Schneider J.,
Allewelt H.,
Cohen A.,
Huang J.,
Tam C. S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847512.47964.b7
Subject(s) - medicine , cohort , clinical endpoint , gastroenterology , randomized controlled trial